{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:22:37Z","timestamp":1783002157026,"version":"3.54.5"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,8,19]],"date-time":"2009-08-19T00:00:00Z","timestamp":1250640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s00280-009-1100-z","type":"journal-article","created":{"date-parts":[[2009,8,18]],"date-time":"2009-08-18T06:44:27Z","timestamp":1250577867000},"page":"931-940","source":"Crossref","is-referenced-by-count":15,"title":["Antimetastatic, antineoplastic, and toxic effects of 4-hydroxycoumarin in a preclinical mouse melanoma model"],"prefix":"10.1007","volume":"65","author":[{"given":"Nohem\u00ed","family":"Salinas-Jazm\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"de la Fuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Jaimez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayra","family":"P\u00e9rez-Tapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"P\u00e9rez-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"Velasco-Vel\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,8,19]]},"reference":[{"key":"1100_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clindermatol.2008.09.001","volume":"27","author":"C Garbe","year":"2009","unstructured":"Garbe C, Leiter U (2009) Melanoma epidemiology and trends. Clin Dermatol 27:3\u20139","journal-title":"Clin Dermatol"},{"key":"1100_CR2","volume-title":"SEER cancer statistics review, 1975\u20132005","author":"LAG Ries","year":"2008","unstructured":"Ries LAG, Melbert D, Krapcho M et al (2008) SEER cancer statistics review, 1975\u20132005. National Cancer Institute, Bethesda, MD"},{"key":"1100_CR3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3322\/canjclin.54.3.131","volume":"54","author":"CM Balch","year":"2004","unstructured":"Balch CM, Soong SJ, Atkins MB et al (2004) An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 54:131\u2013149 quiz 182\u2013134","journal-title":"CA Cancer J Clin"},{"key":"1100_CR4","doi-asserted-by":"crossref","first-page":"6524","DOI":"10.1038\/sj.onc.1206757","volume":"22","author":"T Bogenrieder","year":"2003","unstructured":"Bogenrieder T, Herlyn M (2003) Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22:6524\u20136536","journal-title":"Oncogene"},{"key":"1100_CR5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrc727","volume":"2","author":"JD Hood","year":"2002","unstructured":"Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91\u2013100","journal-title":"Nat Rev Cancer"},{"key":"1100_CR6","first-page":"163","volume":"1775","author":"S Hehlgans","year":"2007","unstructured":"Hehlgans S, Haase M, Cordes N (2007) Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta 1775:163\u2013180","journal-title":"Biochim Biophys Acta"},{"key":"1100_CR7","first-page":"183","volume":"51","author":"MA Velasco-Velazquez","year":"1999","unstructured":"Velasco-Velazquez MA, Molina-Guarneros JA, Mendoza-Patino N et al (1999) Integrins and integrin-associated molecules: targets for the development of antimetastatic therapies. Rev Invest Clin 51:183\u2013193","journal-title":"Rev Invest Clin"},{"key":"1100_CR8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1475-2867-8-8","volume":"8","author":"MA Velasco-Velazquez","year":"2008","unstructured":"Velasco-Velazquez MA, Salinas-Jazmin N, Mendoza-Patino N, Mandoki JJ (2008) Reduced paxillin expression contributes to the antimetastatic effect of 4-hydroxycoumarin on B16\u2013F10 melanoma cells. Cancer Cell Int 8:8","journal-title":"Cancer Cell Int"},{"key":"1100_CR9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0304-3835(03)00333-1","volume":"198","author":"MA Velasco-Velazquez","year":"2003","unstructured":"Velasco-Velazquez MA, Agramonte-Hevia J, Barrera D et al (2003) 4-Hydroxycoumarin disorganizes the actin cytoskeleton in B16\u2013F10 melanoma cells but not in B82 fibroblasts, decreasing their adhesion to extracellular matrix proteins and motility. Cancer Lett 198:179\u2013186","journal-title":"Cancer Lett"},{"key":"1100_CR10","doi-asserted-by":"crossref","unstructured":"(1988) UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 58:109\u2013113","DOI":"10.1038\/bjc.1988.174"},{"key":"1100_CR11","first-page":"751","volume":"290","author":"AJ Quick","year":"1974","unstructured":"Quick AJ (1974) Letter: normal values for coagulation tests. N Engl J Med 290:751","journal-title":"N Engl J Med"},{"key":"1100_CR12","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/ajcp\/36.3.212","volume":"36","author":"RR Proctor","year":"1961","unstructured":"Proctor RR, Rapaport SI (1961) The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 36:212\u2013219","journal-title":"Am J Clin Pathol"},{"key":"1100_CR13","doi-asserted-by":"crossref","first-page":"F590","DOI":"10.1152\/ajprenal.00324.2003","volume":"286","author":"Z Qi","year":"2004","unstructured":"Qi Z, Whitt I, Mehta A et al (2004) Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal Physiol 286:F590\u2013F596","journal-title":"Am J Physiol Renal Physiol"},{"key":"1100_CR14","volume-title":"Pathobiology of the aging mouse","author":"U Mohr","year":"1996","unstructured":"Mohr U, Dungworth DL, Capen CC et al (1996) Pathobiology of the aging mouse. ILSI Press, Washington, DC"},{"key":"1100_CR15","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1248\/bpb.31.1343","volume":"31","author":"AC Luchini","year":"2008","unstructured":"Luchini AC, Rodrigues-Orsi P, Cestari SH et al (2008) Intestinal anti-inflammatory activity of coumarin and 4-hydroxycoumarin in the trinitrobenzenesulphonic acid model of rat colitis. Biol Pharm Bull 31:1343\u20131350","journal-title":"Biol Pharm Bull"},{"key":"1100_CR16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.micinf.2006.10.001","volume":"9","author":"T Stefanova","year":"2007","unstructured":"Stefanova T, Nikolova N, Michailova A et al (2007) Enhanced resistance to Salmonella enterica serovar Typhimurium infection in mice after coumarin treatment. Microbes Infect 9:7\u201314","journal-title":"Microbes Infect"},{"key":"1100_CR17","first-page":"107","volume":"6","author":"TH Stefanova","year":"2007","unstructured":"Stefanova TH, Nikolova NJ, Toshkova RA, Neychev HO (2007) Antitumor and immunomodulatory effect of coumarin and 7-hydroxycoumarin against Sarcoma 180 in mice. J Exp Ther Oncol 6:107\u2013115","journal-title":"J Exp Ther Oncol"},{"key":"1100_CR18","unstructured":"Orozco Arreaga A (2000) Estudio in vivo del efecto antineoplasico de la cumarina en un modelo de melanoma murino. Dissertation, Universidad Nacional Aut\u00f3noma de M\u00e9xico"},{"key":"1100_CR19","doi-asserted-by":"crossref","unstructured":"Cruzan G, Bus J, Banton M et al (2009) Mouse specific lung tumors from CYP2F2-mediated cytotoxic metabolism: an endpoint\/toxic response where data from multiple chemicals converge to support a mode of action. Regul Toxicol Pharmacol. doi: 10.1016\/j.yrtph.2009.07.002","DOI":"10.1016\/j.yrtph.2009.07.002"},{"key":"1100_CR20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0278-6915(02)00227-2","volume":"41","author":"SL Born","year":"2003","unstructured":"Born SL, Api AM, Ford RA et al (2003) Comparative metabolism and kinetics of coumarin in mice and rats. Food Chem Toxicol 41:247\u2013258","journal-title":"Food Chem Toxicol"},{"key":"1100_CR21","first-page":"917","volume":"21","author":"S Kawaii","year":"2001","unstructured":"Kawaii S, Tomono Y, Ogawa K et al (2001) The antiproliferative effect of coumarins on several cancer cell lines. Anticancer Res 21:917\u2013923","journal-title":"Anticancer Res"},{"key":"1100_CR22","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1158\/0008-5472.CAN-07-6849","volume":"68","author":"D Barkan","year":"2008","unstructured":"Barkan D, Kleinman H, Simmons JL et al (2008) Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res 68:6241\u20136250","journal-title":"Cancer Res"},{"key":"1100_CR23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1200\/JCO.1990.8.2.325","volume":"8","author":"FH Dexeus","year":"1990","unstructured":"Dexeus FH, Logothetis CJ, Sella A et al (1990) Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma. J Clin Oncol 8:325\u2013329","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"1100_CR24","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1007\/BF01377123","volume":"120","author":"JL Mohler","year":"1994","unstructured":"Mohler JL, Williams BT, Thompson IM, Marshall ME (1994) Coumarin (1, 2-benzopyrone) for the treatment of prostatic carcinoma. J Cancer Res Clin Oncol 120(Suppl):S35\u2013S38","journal-title":"J Cancer Res Clin Oncol"},{"issue":"Suppl","key":"1100_CR25","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/BF01377114","volume":"120","author":"ME Marshall","year":"1994","unstructured":"Marshall ME, Kervin K, Benefield C et al (1994) Growth-inhibitory effects of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin on human malignant cell lines in vitro. J Cancer Res Clin Oncol 120(Suppl):S3\u2013S10","journal-title":"J Cancer Res Clin Oncol"},{"key":"1100_CR26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00008390-199906000-00005","volume":"9","author":"FA Jimenez-Orozco","year":"1999","unstructured":"Jimenez-Orozco FA, Molina-Guarneros JA, Mendoza-Patino N et al (1999) Cytostatic activity of coumarin metabolites and derivatives in the B16\u2013F10 murine melanoma cell line. Melanoma Res 9:243\u2013247","journal-title":"Melanoma Res"},{"key":"1100_CR27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.lungcan.2003.09.005","volume":"43","author":"JS Lopez-Gonzalez","year":"2004","unstructured":"Lopez-Gonzalez JS, Prado-Garcia H, Aguilar-Cazares D et al (2004) Apoptosis and cell cycle disturbances induced by coumarin and 7-hydroxycoumarin on human lung carcinoma cell lines. Lung Cancer 43:275\u2013283","journal-title":"Lung Cancer"},{"key":"1100_CR28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0169-5002(01)00263-X","volume":"34","author":"FA Jimenez-Orozco","year":"2001","unstructured":"Jimenez-Orozco FA, Lopez-Gonzalez JS, Nieto-Rodriguez A et al (2001) Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin. Lung Cancer 34:185\u2013194","journal-title":"Lung Cancer"},{"key":"1100_CR29","first-page":"93","volume":"59","author":"NB Piller","year":"1978","unstructured":"Piller NB (1978) A morphological assessment of the stimulatory effect of coumarin on macrophages. Br J Exp Pathol 59:93\u201396","journal-title":"Br J Exp Pathol"},{"key":"1100_CR30","first-page":"39","volume":"5","author":"TJ Hardt","year":"1983","unstructured":"Hardt TJ, Ritschel WA (1983) The effect of coumarin and 7-hydroxycoumarin on in vitro macrophage phagocytosis of latex particles. Methods Find Exp Clin Pharmacol 5:39\u201343","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"1100_CR31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11912-008-0067-y","volume":"10","author":"J Villanueva","year":"2008","unstructured":"Villanueva J, Herlyn M (2008) Melanoma and the tumor microenvironment. Curr Oncol Rep 10:439\u2013446","journal-title":"Curr Oncol Rep"},{"key":"1100_CR32","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1472-8206.1996.tb00607.x","volume":"10","author":"D Ratanasavanh","year":"1996","unstructured":"Ratanasavanh D, Lamiable D, Biour M et al (1996) Metabolism and toxicity of coumarin on cultured human, rat, mouse and rabbit hepatocytes. Fundam Clin Pharmacol 10:504\u2013510","journal-title":"Fundam Clin Pharmacol"},{"key":"1100_CR33","first-page":"1","volume":"422","author":"NTP (National Toxicology Program)","year":"1993","unstructured":"NTP (National Toxicology Program) (1993) NTP toxicology and carcinogenesis studies of coumarin (CAS No. 91\u201364-5) in F344\/N rats and B6C3F1 mice (gavage studies). Natl Toxicol Program Tech Rep Ser 422:1\u2013340","journal-title":"Natl Toxicol Program Tech Rep Ser"},{"key":"1100_CR34","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0015-6264(79)90289-X","volume":"17","author":"AJ Cohen","year":"1979","unstructured":"Cohen AJ (1979) Critical review of the toxicology of coumarin with special reference to interspecies differences in metabolism and hepatotoxic response and their significance to man. Food Cosmet Toxicol 17:277\u2013289","journal-title":"Food Cosmet Toxicol"},{"key":"1100_CR35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/978-3-642-69132-4_2","volume":"7","author":"BG Lake","year":"1984","unstructured":"Lake BG (1984) Investigations into the mechanism of coumarin-induced hepatotoxicity in the rat. Arch Toxicol Suppl 7:16\u201329","journal-title":"Arch Toxicol Suppl"},{"key":"1100_CR36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/toxsci\/kfh162","volume":"80","author":"JD Vassallo","year":"2004","unstructured":"Vassallo JD, Hicks SM, Daston GP, Lehman-McKeeman LD (2004) Metabolic detoxification determines species differences in coumarin-induced hepatotoxicity. Toxicol Sci 80:249\u2013257","journal-title":"Toxicol Sci"},{"key":"1100_CR37","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0278-6915(09)80007-0","volume":"32","author":"BG Lake","year":"1994","unstructured":"Lake BG, Evans JG, Lewis DF, Price RJ (1994) Comparison of the hepatic effects of coumarin, 3,4-dimethylcoumarin, dihydrocoumarin and 6-methylcoumarin in the rat. Food Chem Toxicol 32:743\u2013751","journal-title":"Food Chem Toxicol"},{"key":"1100_CR38","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0041-008X(89)90336-0","volume":"97","author":"BG Lake","year":"1989","unstructured":"Lake BG, Gray TJ, Evans JG et al (1989) Studies on the mechanism of coumarin-induced toxicity in rat hepatocytes: comparison with dihydrocoumarin and other coumarin metabolites. Toxicol Appl Pharmacol 97:311\u2013323","journal-title":"Toxicol Appl Pharmacol"},{"key":"1100_CR39","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/toxsci\/kfh237","volume":"82","author":"JD Vassallo","year":"2004","unstructured":"Vassallo JD, Hicks SM, Born SL, Daston GP (2004) Roles for epoxidation and detoxification of coumarin in determining species differences in clara cell toxicity. Toxicol Sci 82:26\u201333","journal-title":"Toxicol Sci"},{"key":"1100_CR40","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/096032718900800612","volume":"8","author":"D Cox","year":"1989","unstructured":"Cox D, O\u2019Kennedy R, Thornes RD (1989) The rarity of liver toxicity in patients treated with coumarin (1,2-benzopyrone). Hum Toxicol 8:501\u2013506","journal-title":"Hum Toxicol"},{"key":"1100_CR41","doi-asserted-by":"crossref","first-page":"391","DOI":"10.5694\/j.1326-5377.1995.tb139958.x","volume":"162","author":"JR Casley-Smith","year":"1995","unstructured":"Casley-Smith JR (1995) Frequency of coumarin hepatotoxicity. Med J Aust 162:391","journal-title":"Med J Aust"},{"key":"1100_CR42","volume-title":"Coumarins biology, applications and mode of action","author":"O Pelkonen","year":"1997","unstructured":"Pelkonen O, Raunio H, Rautio A, Pasanen M (1997) The metabolism of coumarin. In: O\u2019Kennedy R, Thornes RD (eds) Coumarins biology, applications and mode of action. Wiley, New York"},{"key":"1100_CR43","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/toxsci\/51.2.300","volume":"51","author":"SL Born","year":"1999","unstructured":"Born SL, Fix AS, Caudill D, Lehman-McKeeman LD (1999) Development of tolerance to Clara cell necrosis with repeat administration of coumarin. Toxicol Sci 51:300\u2013309","journal-title":"Toxicol Sci"},{"key":"1100_CR44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1006\/taap.1998.8442","volume":"151","author":"SL Born","year":"1998","unstructured":"Born SL, Fix AS, Caudill D, Lehman-McKeeman LD (1998) Selective Clara cell injury in mouse lung following acute administration of coumarin. Toxicol Appl Pharmacol 151:45\u201356","journal-title":"Toxicol Appl Pharmacol"},{"key":"1100_CR45","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0022-3565(24)37977-7","volume":"288","author":"X Zhuo","year":"1999","unstructured":"Zhuo X, Gu J, Zhang QY et al (1999) Biotransformation of coumarin by rodent and human cytochromes P-450: metabolic basis of tissue-selective toxicity in olfactory mucosa of rats and mice. J Pharmacol Exp Ther 288:463\u2013471","journal-title":"J Pharmacol Exp Ther"},{"key":"1100_CR46","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1124\/dmd.30.5.483","volume":"30","author":"SL Born","year":"2002","unstructured":"Born SL, Caudill D, Fliter KL, Purdon MP (2002) Identification of the cytochromes P450 that catalyze coumarin 3,4-epoxidation and 3-hydroxylation. Drug Metab Dispos 30:483\u2013487","journal-title":"Drug Metab Dispos"},{"key":"1100_CR47","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1021\/bi00475a012","volume":"29","author":"PT Nhamburo","year":"1990","unstructured":"Nhamburo PT, Kimura S, McBride OW et al (1990) The human CYP2F gene subfamily: identification of a cDNA encoding a new cytochrome P450, cDNA-directed expression, and chromosome mapping. Biochemistry 29:5491\u20135499","journal-title":"Biochemistry"},{"key":"1100_CR48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1124\/jpet.103.062901","volume":"309","author":"RM Baldwin","year":"2004","unstructured":"Baldwin RM, Jewell WT, Fanucchi MV et al (2004) Comparison of pulmonary\/nasal CYP2F expression levels in rodents and rhesus macaque. J Pharmacol Exp Ther 309:127\u2013136","journal-title":"J Pharmacol Exp Ther"},{"key":"1100_CR49","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1006\/bbrc.1997.7529","volume":"239","author":"X Ye","year":"1997","unstructured":"Ye X, Lu L, Gill SS (1997) Suppression of cytochrome P450 Cyp2f2 mRNA levels in mice by the peroxisome proliferator diethylhexylphthalate. Biochem Biophys Res Commun 239:660\u2013665","journal-title":"Biochem Biophys Res Commun"},{"key":"1100_CR50","first-page":"822","volume":"26","author":"T Su","year":"1998","unstructured":"Su T, He W, Gu J et al (1998) Differential xenobiotic induction of CYP2A5 in mouse liver, kidney, lung, and olfactory mucosa. Drug Metab Dispos 26:822\u2013824","journal-title":"Drug Metab Dispos"},{"key":"1100_CR51","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1160\/TH07-04-0297","volume":"98","author":"K Dahri","year":"2007","unstructured":"Dahri K, Loewen P (2007) The risk of bleeding with warfarin: a systematic review and performance analysis of clinical prediction rules. Thromb Haemost 98:980\u2013987","journal-title":"Thromb Haemost"},{"key":"1100_CR52","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1161\/01.CIR.89.1.432","volume":"89","author":"RL Mueller","year":"1994","unstructured":"Mueller RL, Scheidt S (1994) History of drugs for thrombotic disease. Discovery, development, and directions for the future. Circulation 89:432\u2013449","journal-title":"Circulation"},{"key":"1100_CR53","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/0049825021000022302","volume":"33","author":"LB Weymarn von","year":"2003","unstructured":"von Weymarn LB, Murphy SE (2003) CYP2A13-catalysed coumarin metabolism: comparison with CYP2A5 and CYP2A6. Xenobiotica 33:73\u201381","journal-title":"Xenobiotica"},{"key":"1100_CR54","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/03602539008991449","volume":"22","author":"D Egan","year":"1990","unstructured":"Egan D, O\u2019Kennedy R, Moran E et al (1990) The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. Drug Metab Rev 22:503\u2013529","journal-title":"Drug Metab Rev"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1100-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-009-1100-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1100-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T19:43:25Z","timestamp":1739303005000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-009-1100-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,19]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["1100"],"URL":"https:\/\/doi.org\/10.1007\/s00280-009-1100-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,19]]}}}